2 3 23 5 3 10 22 12 23 15 16 24 18 4 27 23 28 24 31 33 33 34 36 24 38 25 39 40 40 1

5 6 150 ips TV ipad 2

11 9 20 20 90 1 1996 8 2003 1 3

4

23 VEGF 5

6

7

8

9

3 VEGF GPR91 PDR ERM VEGF 2008 7 2010 10 PDR 41 45 64.1 11.0 ERM 20 21 66.7 6.9 PDR IVB APDR 20 21 64.9 8.4 QPDR 21 24 63.4 13.0 IVB IVB 35 40 55.6 11.8 VEGF ELISA PDR 2.10 M vs ERM 1.27 M P=0.03 APDR 3.42 M QPDR 0.94 M IVB 1.17 M APDR vs QPDR P<0.01 APDR vs IVB P<0.01 VEGF APDR 1673pg/ml QPDR 102pg/ml IVB APDR IVB 2868mIU/ml >APDR 733mIU/ml 10

>QPDR 319mIU/ml PDR VEGF IVB VEGF VEGF GPR91 11

22 22 1 1 22 12 31 12

13

14

4 23 11 20 15

11 19 50 60 16

20 11 10 22 23 10 12 13 8:03 NO.1 2 23 11 20 17

24 18

19

20

21

22

23

24

25

26

4 prospective study 2008 3 2010 4 (PEA ) Vit SA60AT Alcon 1 3 6 12 Pentacam A Tomey NIDEK IOL PEA 22 28 7 9 15 19 74.1 Vit 30 30 7 7 23 23 67.2 (P<0.05) Pentacam 3 PEA Vit (P<0.05) A PEA Vit PEA Vit A PEA Vit 27

23 23 1 1 23 12 31 28

29

30

5 24 11 18 11 31

32

23 24 AM8:30~PM5:00 21 H24.4.23 23 H25.4.19 33

23 11 34

35

~ ~ 7 NTT 36

25 7 SLO FAG 1 8 11 37

24 38

25 39

25 11 9 18 30 40

41